Executive Summary
The Tata 1mg app is a digital health platform that brings together medicine ordering, lab tests with home sample collection, doctor teleconsultation and health products in one place. Three factors define it today: 1) breadth across the care journey, so a patient can consult a doctor, get tests and order medicines without leaving the app; 2) its own diagnostics network, a profitable business with more than ₹600 crore in annualised revenue; and 3) the trust of the Tata brand, reinforced by integration with Tata Neu and its loyalty programme.
The app's unique value proposition is integrated, trustworthy care for everyday and chronic health needs. Its challenge is speed: quick-commerce apps now promise medicines in 10 minutes, and 1mg must compete on urgent needs without losing its hard-won profitability.
This teardown examines the 1mg app's product, user journeys, UX, features, business model and competitive position. For interview preparation, see our Tata 1mg Product Manager Interview Guide.
Introduction
1mg started in 2015 as a medicine information and ordering platform founded by Prashant Tandon, Gaurav Agarwal and Vikas Chauhan. It added diagnostics, consultations and health products, and in 2021 Tata Digital acquired a majority stake, renaming it Tata 1mg. In FY26 it reported revenue of about ₹2,936 crore, up 23%, and said its core businesses turned EBITDA positive from December 2025.
This analysis covers the 1mg app's core flows, design choices, features and economics, and compares it with PharmEasy, Apollo 24/7, Netmeds, MedPlus and quick-commerce pharmacies. It is based on public information, app listings and user feedback. For strategy context, see our Tata 1mg Product Strategy Guide.
Industry coverage of 1mg's FY26 results highlighted diagnostics as the company's profit engine, growing more than 40% a year with double-digit EBITDA margins, a sign that 1mg's future lies in being a health platform rather than only a pharmacy.
Product Overview
Core value proposition: "Your trusted health partner for medicines, tests and doctors, delivered at home."
Target users: urban and semi-urban adults managing their own or family health, especially chronic patients and caregivers.
Key use cases:
- Ordering medicines, especially monthly chronic refills
- Booking lab tests and health checkups with home sample collection
- Consulting doctors online
- Buying health and wellness products
- Looking up medicine information and alternatives
Timeline:
- 2015: 1mg founded
- 2016–2020: Expands to pharmacy, diagnostics and consultations
- 2021: Tata Digital acquires majority stake; Tata 1mg brand
- 2022: Integration with Tata Neu launches
- 2025: Express delivery expands amid quick-commerce competition
- December 2025: Core businesses EBITDA positive
- 2026: Express delivery in 10 cities, sub-15-minute pilots, plans for about 500 offline stores
1mg has evolved from a medicine information site into an integrated health platform, with diagnostics and chronic care as its strongest pillars.
User Journey Deep-Dive
Onboarding: sign up with a mobile number and OTP; optional health profile and family members.
Medicine ordering:
- Search or upload a prescription.
- Compare brands and substitutes.
- Add to cart; prescription verification.
- Choose delivery (standard or express where available); apply membership benefits or NeuCoins (via Tata Neu).
- Track the order; receive delivery.
Lab tests:
- Choose a test or package.
- Select slot and address; get preparation instructions.
- Phlebotomist visit; sample collection.
- Digital report; optional consult.
Teleconsultation:
- Choose speciality or describe symptoms.
- Get matched with a doctor; chat, audio or video.
- Receive a digital prescription; order medicines or tests.
Pain points and responses:
- Prescription holds and expiries cause reorder friction; clearer validity information and renewal consults help.
- Lab visit delays frustrate users; slot management and tracking are key improvement areas.
- Delivery speed lags quick-commerce for urgent needs; express delivery and stores aim to close the gap.
Express delivery in 30–60 minutes and planned offline stores directly address the biggest competitive gap: urgent medicine needs.
UX & Design Analysis
Home screen: entry points for medicines, lab tests, consultations and health products, plus offers and reorder shortcuts.
Search and product pages: detailed medicine information (composition, uses, side effects), substitutes and prices. This information depth is a long-standing 1mg strength.
Checkout: prescription upload, delivery options, membership benefits and payment.
Reports and records: lab reports and prescriptions are stored in the app.
| UX element | Strength | Opportunity |
|---|---|---|
| Medicine information | Detailed, trusted | Simpler summaries for older users |
| Prescription upload | Clear prompts | Earlier feedback before checkout |
| Lab booking | Wide test catalogue | Slot reliability and tracking |
| Reports | Digital and stored | Plain-language insights and trends |
| Reorder | Shortcuts available | Subscriptions and refill planning |
Compared with quick-commerce apps, 1mg's UX is richer in medicine information and services but slower for urgent purchases. Compared with Apollo 24/7, it is more digital-first but has fewer hospital links.
Feature Analysis
| Feature | Description | User value |
|---|---|---|
| ePharmacy | Wide catalogue with verified dispensing | Convenience and trust |
| Express delivery | 30–60 minutes in 10 cities | Urgent needs |
| Lab tests | Home collection; own labs | Convenience and reliability |
| Teleconsultation | Doctors across specialities | Quick advice and prescriptions |
| Substitutes | Same-molecule alternatives | Savings |
| Membership | Discounts and benefits | Value for frequent users |
| Health products | 1mg and third-party brands | Wellness needs |
| Tata Neu integration | NeuCoins and Tata Neu access | Loyalty rewards |
Innovation highlights: integration of consults, tests and medicines; diagnostics capability; Specialty Pharma services such as patient support programmes.
For PM candidates, 1mg is a strong example of a product where clinical quality, compliance and operations shape every feature decision, from prescription verification to lab slot design.
Business Model Analysis
Revenue streams:
- Medicine sales (ePharmacy margins)
- Diagnostics (test fees; high margin)
- Teleconsultation fees
- DTC health products (1mg brands; profitable)
- Specialty Pharma and patient support programmes
- Membership fees
- Advertising and partnerships with pharmaceutical and wellness brands
Cost structure: medicine procurement, warehousing, delivery, phlebotomists and labs, doctors, technology and marketing.
Profitability: core businesses EBITDA positive since December 2025; consolidated net loss persists at the healthcare entity.
Diagnostics and DTC products carry higher margins than medicine sales, so cross-selling them to pharmacy customers is central to 1mg's economics.
Competitive Analysis
| Competitor | Strengths | Weaknesses | Positioning vs 1mg |
|---|---|---|---|
| PharmEasy | Scale, Thyrocare diagnostics | Financial stress | Direct rival |
| Apollo 24/7 | Pharmacy network, hospitals | Less digital-native | Strong omnichannel rival |
| Netmeds | Reliance backing | Lower focus | Price competitor |
| MedPlus | Store network, discounts | Limited digital services | Offline price leader |
| Zepto, Blinkit, Swiggy + PharmEasy | Speed | Limited assortment and services | Urgent needs |
1mg's advantages: integrated services, own diagnostics, Tata trust, profitability in core businesses. Vulnerabilities: speed, price competition and offline presence (being built).
1mg's best position is as the trusted platform for ongoing health management, with reliable rather than fastest-possible delivery for urgent needs.
FAQs
What makes the Tata 1mg app unique in the market?
It combines medicines, lab tests with its own diagnostics network, doctor consultations and health products in one app, backed by the Tata brand and integrated with Tata Neu's loyalty programme.
How does Tata 1mg make money?
Mainly through medicine sales and diagnostics, plus consultation fees, its own health product brands, Specialty Pharma services, memberships and partnerships. Diagnostics and health products carry higher margins.
What changed at Tata 1mg in 2025–26?
Core businesses turned EBITDA positive in December 2025, diagnostics crossed ₹600 crore in annualised revenue, express delivery expanded to 10 cities with sub-15-minute pilots, and the company announced plans for about 500 offline stores.
How has Tata 1mg evolved since launch?
- 2015: Medicine information and ordering
- 2016–2020: Diagnostics and consultations added
- 2021: Tata Digital majority stake
- 2025–26: Profitability in core businesses, express delivery and omnichannel expansion
Related Guides Section
📖 Tata 1mg Product Strategy Guide → 1mg's strategy across pharmacy, diagnostics, express delivery and stores.
📖 Tata 1mg PM Interview Guide → Rounds, case questions and preparation.
📖 Tata 1mg Product Manager Salary Guide → 2026 INR compensation by level.
Disclaimer: This product teardown is based on publicly available information and independent analysis. It is an external view of the Tata 1mg app and not official documentation or insider information. Features and terms change frequently; verify current details in the app.
